While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...

RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. ...

Shares of Agios Pharmaceuticals jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the ...

Discover why pharma sector leaders and AI innovation may drive the S&P 500 to 9,000 by 2026. Explore top stocks, growth ...

The market for weight-loss drug is expected to expand to more than $150 billion in revenue by the early 2030s, thanks to the ...

The bottom line of the company was also affected by a review of its intercompany receivables, resulting in an exceptional ...

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

New institution, envisioned by the late businessman Petch Osathanugrah, boosts Thai capital as burgeoning art destination ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

Several Indian companies are preparing to launch generic versions of GLP-1 category drug Semaglutide in India ...

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs ...